IGI Logo

Zydus Lifesciences is currently trading at Rs. 997.60, up by 2.85 points or 0.29% from its previous closing of Rs. 994.75 on the BSE.

The scrip opened at Rs. 999.25 and has touched a high and low of Rs. 999.95 and Rs. 989.65 respectively. So far 9899 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 797.05 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 999.95 and Rs. 960.60 respectively. The current market cap of the company is Rs. 100386.93 crore.

The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 18.26% and 6.74% respectively.

Zydus Lifesciences’ step down subsidiary -- Zydus MedTech (France) SAS has completed block acquisition of 85.6% equity shares of Amplitude Surgical SA, France (Target Entity). As a result, Zydus MedTech France now holds 85.6% of the share capital and voting rights of the Target Entity. 

Zydus MedTech France will file on July 30, 2025, a simplified mandatory tender offer for all the remaining outstanding shares of the Target Entity at a price of Euro 6.25 per share, identical to the price paid for the Block Acquisition. Considering the undertaking received from seven shareholders to participate in tender offer representing in aggregate 4.7% of share capital and voting rights, Zydus MedTech France will be in a position to hold more than 90% of the capital and voting rights of the Target Entity upon completion of the Offer. Zydus MedTech France will subsequently request the implementation of a squeeze-out.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.